Patents by Inventor John K. Amory

John K. Amory has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitor compounds for male contraception
    Patent number: 11548875
    Abstract: Pyrazole compounds and piperazine compounds that are inhibitors of ALDH1A1 and ALDH1A2 and methods for using the pyrazole compounds and piperazine compounds in male contraceptive compositions for preventing spermatogenesis.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: January 10, 2023
    Assignee: University of Washington
    Inventors: Alex S. Goldstein, John K. Amory, Jisun Paik, Michael Haenisch, Nina Isoherranen, Piper Treuting, Charles H. Muller
  • INHIBITOR COMPOUNDS FOR MALE CONTRACEPTION
    Publication number: 20210332030
    Abstract: Pyrazole compounds and piperazine compounds that are inhibitors of ALDH1A1 and ALDH1A2 and methods for using the pyrazole compounds and piperazine compounds in male contraceptive compositions for preventing spermatogenesis.
    Type: Application
    Filed: December 12, 2019
    Publication date: October 28, 2021
    Applicant: University of Washington
    Inventors: Alex S. Goldstein, John K. Amory, Jisun Paik, Michael Haenisch, Nina Isoherranen, Piper Treuting, Charles H. Muller
  • Methods for treating testosterone deficiency in men and methods for precise dosing of UGT2B17 substrate drugs
    Patent number: 11131677
    Abstract: Treatment of testosterone deficiency in men by a precision medicine approach using a biomarker of activity of UGT2B17 that is involved in testosterone urinary elimination. By inhibiting UGT2B17, alone or in combination with administration of testosterone, testosterone deficiency in men can be treatable. Further, a method of dose selection for precise dosing of UGT2B17 substrate drugs is provided. Additionally, methods for safe dosing of pharmaceutical agents that undergo UGT2B17-mediated acyl glucuronidation are provided.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: September 28, 2021
    Assignee: University of Washington
    Inventors: Bhagwat Prasad, Abdul Basit, Haeyoung Zhang, John K. Amory
  • METHODS FOR TREATING TESTOSTERONE DEFICIENCY IN MEN AND METHODS FOR PRECISE DOSING OF UGT2B17 SUBSTRATE DRUGS
    Publication number: 20190307773
    Abstract: Treatment of testosterone deficiency in men by a precision medicine approach using a biomarker of activity of UGT2B17 that is involved in testosterone urinary elimination. By inhibiting UGT2B17, alone or in combination with administration of testosterone, testosterone deficiency in men can be treatable. Further, a method of dose selection for precise dosing of UGT2B17 substrate drugs is provided. Additionally, methods for safe dosing of pharmaceutical agents that undergo UGT2B17-mediated acyl glucuronidation are provided.
    Type: Application
    Filed: April 10, 2019
    Publication date: October 10, 2019
    Applicant: University of Washington
    Inventors: Bhagwat Prasad, Abdul Basit, Haeyoung Zhang, John K. Amory
  • Oral androgen therapy using modulators of testosterone bioavailability
    Patent number: 7138389
    Abstract: This invention provides methods of treating a mammalian subject in need of androgen therapy by orally administering to the subject testosterone, a testosterone ester, or a testosterone precursor in an oil vehicle and by administering to the subject a modulator such as finasteride or dutasteride which increases testosterone bioavailability in the subject.
    Type: Grant
    Filed: November 15, 2004
    Date of Patent: November 21, 2006
    Assignee: University of Washington
    Inventors: John K. Amory, William J. Bremner